Verona Pharma PLC (VRNA)
37.86
-0.99
(-2.55%)
USD |
NASDAQ |
Nov 21, 16:00
37.93
+0.07
(+0.18%)
After-Hours: 20:00
Verona Pharma Enterprise Value: 2.882B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.882B |
| November 20, 2024 | 2.963B |
| November 19, 2024 | 2.901B |
| November 18, 2024 | 2.643B |
| November 15, 2024 | 2.702B |
| November 14, 2024 | 2.678B |
| November 13, 2024 | 2.806B |
| November 12, 2024 | 2.975B |
| November 11, 2024 | 3.047B |
| November 08, 2024 | 2.941B |
| November 07, 2024 | 2.908B |
| November 06, 2024 | 2.860B |
| November 05, 2024 | 2.925B |
| November 04, 2024 | 2.906B |
| November 01, 2024 | 2.646B |
| October 31, 2024 | 2.561B |
| October 30, 2024 | 2.582B |
| October 29, 2024 | 2.539B |
| October 28, 2024 | 2.493B |
| October 25, 2024 | 2.555B |
| October 24, 2024 | 2.601B |
| October 23, 2024 | 2.642B |
| October 22, 2024 | 2.637B |
| October 21, 2024 | 2.646B |
| October 18, 2024 | 2.618B |
| Date | Value |
|---|---|
| October 17, 2024 | 2.620B |
| October 16, 2024 | 2.569B |
| October 15, 2024 | 2.572B |
| October 14, 2024 | 2.588B |
| October 11, 2024 | 2.458B |
| October 10, 2024 | 2.351B |
| October 09, 2024 | 2.382B |
| October 08, 2024 | 2.384B |
| October 07, 2024 | 2.407B |
| October 04, 2024 | 2.403B |
| October 03, 2024 | 2.305B |
| October 02, 2024 | 2.133B |
| October 01, 2024 | 2.156B |
| September 30, 2024 | 2.138B |
| September 27, 2024 | 2.051B |
| September 26, 2024 | 1.960B |
| September 25, 2024 | 2.011B |
| September 24, 2024 | 2.125B |
| September 23, 2024 | 2.120B |
| September 20, 2024 | 2.151B |
| September 19, 2024 | 2.103B |
| September 18, 2024 | 2.090B |
| September 17, 2024 | 2.086B |
| September 16, 2024 | 2.165B |
| September 13, 2024 | 2.134B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-12.37M
Minimum
Mar 18 2020
3.047B
Maximum
Nov 11 2024
676.06M
Average
353.50M
Median
Mar 02 2021
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals PLC | -3.355M |
| TC BioPharm (Holdings) PLC | -0.927M |
| Adaptimmune Therapeutics PLC | 26.67M |
| NuCana PLC | -11.87M |
| Autolus Therapeutics PLC | 98.72M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.96M |
| Revenue (Quarterly) | 5.624M |
| Total Expenses (Quarterly) | 44.68M |
| EPS Diluted (Quarterly) | -0.56 |
| Gross Profit Margin (Quarterly) | 90.34% |
| Profit Margin (Quarterly) | -763.9% |
| Earnings Yield | -5.28% |
| Normalized Earnings Yield | -5.264 |